Skip to main content
Jinhe Biotechnology CO.,LTD. logo

Jinhe Biotechnology CO.,LTD. — Investor Relations & Filings

Ticker · 002688 ISIN · CNE100001HK7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,830 across all filing types
Latest filing 2025-09-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002688

About Jinhe Biotechnology CO.,LTD.

https://www.jinhe.com.cn

Jinhe Biotechnology CO.,LTD. specializes in the research, development, and manufacturing of animal health products and feed additives. The company is a prominent global producer of chlortetracycline (CTC), maintaining extensive production capacity for feed-grade antibiotics. Its diverse product portfolio includes veterinary pharmaceuticals such as salinomycin and monensin, alongside a range of biological products and animal vaccines. Jinhe Biotechnology leverages advanced fermentation technology and integrated research capabilities to provide solutions for the livestock and poultry sectors. The company focuses on improving animal growth performance and disease prevention through standardized production processes and a global distribution network. Its operations span the development of specialized additives and the provision of comprehensive veterinary medical products designed to support large-scale animal husbandry.

Recent filings

Filing Released Lang Actions
第六届董事会第三十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by 金河生物科技股份有限公司 (Jinhe Biotechnology Co., Ltd.). It details the approval of a loan credit limit application to a bank, including voting results and meeting legality. There is no financial report, audit, or earnings data presented. The content focuses on board decisions and management actions. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2025-09-24 Chinese
关于部分股票期权注销完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the cancellation of certain stock options under the company's 2024 stock option incentive plan. It details the board meeting decisions, regulatory compliance, and confirms that the cancellation does not affect the company's capital structure or financial results. There is no financial report, earnings data, or detailed financial analysis. The document is a formal announcement about a capital-related event (stock option cancellation) but does not involve new share issuance or repurchase. It fits best under 'Capital/Financing Update' (CAP) as it relates to changes in the company's capital structure through stock option cancellation.
2025-09-24 Chinese
关于开立募集资金暂时补充流动资金专户并签订募集资金四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the opening of a special account for temporarily supplementing working capital with raised funds and the signing of a four-party supervision agreement related to the raised funds. It details the background of the fundraising, the signing of the supervision agreement, and the management and use of the funds. The document does not contain financial statements or substantive financial data but rather describes the administrative and regulatory arrangements for the use of the raised funds. It is a regulatory announcement about capital management and supervision, fitting the category of Capital/Financing Update (CAP). The document length is 2852 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2025-09-22 Chinese
关于2024年股票期权激励计划授予第一个行权期行权情况暨控股股东及其一致行动人持股比例被动减少触及1%整数倍的公告
Director's Dealing Classification · 95% confidence The document is a detailed announcement regarding the exercise of stock options under the company's 2024 stock option incentive plan. It includes specifics about the number of options exercised, the exercise price, the number of participants, the source of shares, and the impact on shareholding percentages. It also discusses approvals by the board and shareholders, legal opinions, and financial advisor reports. The document is not a full financial report but an announcement of a corporate action related to stock options and changes in shareholding proportions due to the exercise. It also includes information about the passive reduction in the controlling shareholder's stake due to share structure changes. This type of document fits best under the category of "Director's Dealing" (DIRS) because it reports on stock option exercises by directors and senior management, which is a form of insider transaction. It is not a general regulatory filing or a report publication announcement because it contains substantive details about the stock option exercise event and its impact on shareholding. Therefore, the classification is DIRS with high confidence.
2025-09-21 Chinese
第六届监事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 金河生物科技股份有限公司 regarding the use of idle raised funds to temporarily supplement working capital. It includes voting results and confirms compliance with laws and regulations. The document is short (751 characters) and is an official announcement of a board meeting decision rather than a full report or financial statement. It does not contain financial data or detailed financial analysis. It is not a full Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation or voting results announcement for shareholders but a board/management information announcement about a specific decision. Therefore, the best fitting category is Board/Management Information (MANG).
2025-09-19 Chinese
关于归还暂时补充流动资金的闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 金河生物科技股份有限公司 regarding the return of temporarily used idle raised funds to the dedicated fundraising account. It details the approval by the board and supervisory committee, the amount used, and the timeline of returning the funds. The document is short (775 characters) and serves as an update on the use and return of capital raised through non-public issuance. It does not contain financial statements, audit information, or detailed financial analysis. It is an announcement related to capital usage and financing activities, specifically about the temporary use and return of raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-09-19 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.